CVM (Cel-Sci Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by CVM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-26 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2026-08-17 | Robert Eugene Watson | Director | A | — | — |
| 2026-08-17 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2026-08-17 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2026-08-17 | JOHN CIPRIANO | Senior Vice President | A | — | — |
| 2026-08-17 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2026-08-17 | BRUNO JEAN-MARIE BAILLAVOINE | Director | A | — | — |
| 2026-07-01 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2026-07-01 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2026-07-01 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2026-05-18 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2026-05-14 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2026-04-01 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2026-04-01 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2026-04-01 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2026-01-26 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2026-01-05 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2026-01-05 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2026-01-05 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2025-12-05 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2025-10-02 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2025-10-02 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2025-10-02 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2025-07-29 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2025-07-29 | BRUNO JEAN-MARIE BAILLAVOINE | Director | A | — | — |
| 2025-07-29 | Robert Eugene Watson | Director | A | — | — |
| 2025-07-29 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2025-07-29 | Robert Eugene Watson | Director | Buy | — | — |
| 2025-07-29 | JOHN CIPRIANO | Senior Vice President | A | — | — |
| 2025-07-29 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2025-07-28 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2025-07-01 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2025-07-01 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2025-07-01 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2025-04-01 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2025-04-01 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2025-04-01 | PATRICIA B PRICHEP | Chief Financial Officer | A | — | — |
| 2025-01-02 | GEERT R KERSTEN | CEO | A | — | — |
| 2025-01-02 | PATRICIA B PRICHEP | Chief Financial & Operations | A | — | — |
| 2025-01-02 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2024-10-01 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2024-10-01 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2024-10-01 | PATRICIA B PRICHEP | Sr. VP of Operations | A | — | — |
| 2024-07-01 | PATRICIA B PRICHEP | Senior Vice President | A | — | — |
| 2024-07-01 | EYAL TALOR | Chief Scientific Officer | A | — | — |
| 2024-07-01 | GEERT R KERSTEN | Chief Executive Officer | A | — | — |
| 2024-05-10 | Robert Eugene Watson | Director | Buy | — | — |
| 2024-05-09 | GEERT R KERSTEN | Chief Executive Officer | Buy | — | — |
| 2024-05-09 | PATRICIA B PRICHEP | Senior Vice President | Buy | — | — |
| 2024-04-23 | PATRICIA B PRICHEP | Senior Vice President | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 627,689 | — |
| — | Chief Financial Officer | 17,489 | — |
| — | Chief Scientific Officer | 9,318 | — |
| — | Senior Vice President | 4,008 | — |
| — | Director | 3,733 | — |
| — | Senior Vice President | 2,104 | — |
| — | Director | 1,798 | — |
| — | Director | 199 | — |
| — | Director | 47 | — |
| — | President | 33 | — |
| — | Director | 31 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CVM quote page; the site-wide leaderboard is on the insider transactions hub.